Posted by Michael Wonder on 12 Oct 2016
Health Canada greenlights MendeliKABS for the commercialisation of PrMDK-nitisinone
11 October 2016 - MendeliKABS is proud to announce that Health Canada has approved MDK-Nitisinone medication for the treatment of hereditary tyrosinemia type 1.
This is Health Canada's first approval for an hereditary tyrosinemia type 1 medication. Nitisinone is used to treat hereditary tyrosinemia type 1 in combination with adherence to a reduced tyrosine dietary regime. Since its introduction in 1991, this treatment has replaced liver transplantation as a first line treatment for patients with this rare condition.
